Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants

Pediatrics

Volumn 102, Issue 3 I, 1998, Pages 531-537

  Connor, Edward M ^a  

^a MEDIMMUNE   (United States)

Author keywords

Bronchopulmonary dysplasia; MEDI 493; Monoclonal antibody; Palivizumab; Prematurity; Prophylaxis; Respiratory syncytial virus; Synagis

Indexed keywords

ANTIVIRUS AGENT; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; UNCLASSIFIED DRUG;

ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFANT; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TREATMENT OUTCOME; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; BRONCHOPULMONARY DYSPLASIA; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 0031683919     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.102.3.531     Document Type: Article

References (12)

1. Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone; 1995:1501-1519
2. Institute of Medicine Committee on Issues and Priorities for New Vaccine Development. Prospects for immunizing against respiratory syncytial virus. In: New Vaccine Development, Establishing Priorities. Washington, DC: National Academy of Sciences Press; 1988;1:397-409
3. Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329:1524-1530
4. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99:93-99
5. Johnson S, Oliver C, Prince G, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus (RSV). J Infect Dis. 1997;176: 1215-1224
6. Beeler JA, Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol. 1989;63:7:2941-2950
7. Siva Subramanian KN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 1998;17:110-115
8. Saez-Llorens X, Castano E, Sanchez P, et al. Phase I/II, open-label multi-dose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (MEDI-493) administered intramuscularly (IM) in high-risk children. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy; September-October 1997; Toronto, Canada. Abstract H-89
9. de Craen AJM, Vickers AJ, Tijssen JGP, Kleijnen J. Number-needed-to-treat and placebo-controlled trials. Lancet. 1998;351:310
10. Brown WA. The placebo effect. Sci Am. 1998;278:90-95
11. DeVincenzo JF, Malley R, Ramilo O, et al. Viral concentration in upper and lower respiratory secretions from respiratory syncytial virus (RSV) infected children treated with RSV monoclonal antibody (MEDI-493). Pediatr Res. 1998;43:144. Abstract
12. American Academy of Pediatrics, Committee of Infectious Diseases and Committee on Fetus and Newborn. Respiratory syncytial virus immune globulin, intravenous: indications for use. Pediatrics. 1997;99:645-650